Cytokinetics (CYTK) Stock Forecast & Price Target

Cytokinetics is supported by a strong Myqorzo launch, with U.S. 3Q26 revenue of $43.1M, >2,800 dispenses from 3,200 scripts, and >80% paid drug, while commercial coverage rose above 60% and new-to-brand share approached 45%, signaling improving conversion, access, and physician adoption. Its outlook is further strengthened by positive Phase 3 ACACIA-HCM data in nHCM, where statistically significant gains in KCCQ-CSS, pVO2, and other clinical measures suggest a differentiated profile and a meaningful opportunity in a large unmet market with no approved therapy. Additional upside comes from expanding global authorizations, an upcoming MAPLE-HCM PDUFA on November 14, 2026, and a broader HCM franchise that could drive longer-term revenue growth across oHCM and nHCM.

Cytokinetics is viewed negatively because its thesis depends heavily on aficamten/Myqorzo and other pipeline assets that could still fail in ongoing studies or miss approval in nHCM for unforeseen reasons. Even if clinical data are positive, commercialization risk remains high if safety, efficacy, or logistics issues limit uptake in oHCM, or if payers restrict access in the US and reimbursement proves difficult in Europe or China. The outlook is further weakened if clinicians see aficamten as insufficiently differentiated versus mavacamten, preventing meaningful market share capture and leaving the company with limited near-term revenue visibility.